Latest Disease-modifying antirheumatic drug Stories
This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers.
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).
Tokyo, Sept 11, 2012 - (JCN Newswire) - Eisai Co., Ltd.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.